{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=16", "query": { "condition": "HER2 Positive Breast Carcinoma", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 846, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:27:49.502Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03524170", "title": "Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-04-30", "completion_date": "2022-02-10", "has_results": false, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03524170" }, { "nct_id": "NCT03911973", "title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kari Wisinski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-04-17", "completion_date": "2024-07", "has_results": false, "last_update_posted_date": "2024-06-07", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911973" }, { "nct_id": "NCT01983501", "title": "A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Breast Cancers" ], "interventions": [ { "name": "Tucatinib (ONT-380)", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2014-02-28", "completion_date": "2020-09-03", "has_results": false, "last_update_posted_date": "2020-09-21", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Kansas City, Kansas + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01983501" }, { "nct_id": "NCT03725436", "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "TP53 wt Allele", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "MDM2/MDMX Inhibitor ALRN-6924", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-01-24", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725436" }, { "nct_id": "NCT00095706", "title": "Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Bevacizumab (drug), Herceptin (drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 50, "start_date": "2003-06", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2015-09-25", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 18, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 14 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095706" }, { "nct_id": "NCT06671912", "title": "Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage 1 Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Estrogen Receptor-Positive Breast Carcinoma", "HER2-Negative Breast Carcinoma", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Mammogram", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dual X-ray Absorptiometry", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1556, "start_date": "2025-02-19", "completion_date": "2031-11-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 728, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06671912" }, { "nct_id": "NCT06105632", "title": "A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "PF-07220060 CDK4 inhibitor", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2024-01-09", "completion_date": "2028-01-21", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 9, "location_summary": "Irvine, California • Los Angeles, California • Newport Beach, California + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06105632" }, { "nct_id": "NCT02060253", "title": "Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "ganetespib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "pertuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-04", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060253" }, { "nct_id": "NCT03050398", "title": "A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-06-07", "completion_date": "2019-03-08", "has_results": true, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 6, "location_summary": "Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Florence", "state": "South Carolina" }, { "city": "Rock Hill", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050398" }, { "nct_id": "NCT02760030", "title": "Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor and/or Progesterone Receptor Positive", "HER2/Neu Negative", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Aromatase Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "FEMALE", "summary": "65 Years and older · Female only" }, "enrollment_count": 14, "start_date": "2017-02-16", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-16T10:27:49.502Z", "location_count": 3, "location_summary": "Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio", "locations": [ { "city": "Edgewood", "state": "Kentucky" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760030" } ] }